AstraZeneca to acquire the China unit from FibroGen for $160m.

AstraZeneca, a pharmaceutical and biotechnology company, agreed to acquire the China unit from FibroGen, a biopharmaceutical company focused on development of novel therapies, for $160m. “Today, we announced the sale of FibroGen China to AstraZeneca, our long-time strategic partner for roxadustat in China, bolstering our company on several fronts. It strengthens our financial position, meaningfully extending our cash runway into 2027, and enables us to continue progressing the clinical development program for FG-3246, our first-in-class, CD46 targeting antibody drug conjugate, and FG-3180, our companion PET imaging agent, in mCRPC,” Thane Wettig, FibroGen CEO.